Managing LDL cholesterol levels in patients with cardiovascular disease through a pharmacist-led program

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This initiative focuses on patients who have experienced an atherosclerotic cardiovascular disease (ASCVD) event and are receiving follow-up care at Intermountain Health. Eligible participants will be randomly assigned to receive either targeted LDL-C management by a clinical pharmacy team or usual care. The goal is to improve adherence to statin and lipid-lowering therapies and achieve guideline-recommended LDL-C levels of less than 70 mg/dL. Data will be collected for one year following randomization to assess the effectiveness of the intervention.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Male or female \>18 years of age
2. Receive follow-up care with Intermountain Health
3. Value-based patient (as defined in the EDW)
4. Documentation of an ASCVD diagnosis, by 1 of the following:

   * Coronary artery disease (Primary inpatient CAD diagnosis during index encounter; Primary inpatient MI diagnosis during index encounter; PCI during index encounter; or CABG during index encounter
   * Cerebrovascular accident (Primary inpatient ischemic stroke diagnosis during index encounter; Carotid endarterectomy during index encounter; or Carotid stent during index encounter)
   * Peripheral arterial disease (Bypass or percutaneous intervention during index encounter)

Exclusion Criteria:

1. Patient age \<18 years.
2. Receipt of or expected receipt of palliative care, expected discharge to hospice, or long-term care facility (i.e., skilled nursing facility).
3. Pregnant or lactating women

Where it's running

• Intermountain Healthcare Hospitals and Clinics
  Salt Lake City, Utah, United States Recruiting

Study contacts

• Study coordinator: Kirk U Knowlton, MD
• Email: kirk.knowlton@imail.org
• Phone: 801-507-4757

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Characterizing Subclinical ASCVD in Childhood Cancer Survivors

  This study tests whether detailed heart and blood vessel imaging and blood tests can reveal early signs of atherosclerosis in adult survivors of childhood cancer compared with community controls.

  Recruiting St. Jude Children's Research Hospital · Memphis, Tennessee · NCT07594392

• HRS9531 for atherosclerotic cardiovascular disease

  This study tests whether HRS9531, compared with placebo, can reduce major adverse cardiovascular events in people with ASCVD.

  Recruiting Phase 3 Fujian Shengdi Pharmaceutical Co., Ltd. · Beijing, Beijing Municipality · NCT07551492

• Long-term use of inclisiran, evolocumab, and alirocumab in real-world care

  This study tests whether people with high cholesterol medications stick with their PCSK9 inhibitors and inclisiran over the long term in everyday clinical practice.

  Recruiting Novartis · Basel · NCT07543731

• Targeted lipid optimization program to improve LDL-C control in adults with ASCVD

  This program will test whether a targeted education-based lipid optimization program helps adults with ASCVD and high LDL-C reach recommended LDL-C targets better than usual care.

  Recruiting Phase 4 Novartis · Abu Dhabi · NCT07034690

• Using a genetic blood-pressure risk score to guide care for adults with high blood pressure

  This trial will test whether giving adults aged 18–55 with hypertension and poor cardiovascular health their genetic risk score for systolic blood pressure plus structured genomic counseling helps them lower blood pressure and improve healthy habits over 12 months.

  Recruiting University of Alabama at Birmingham · Birmingham, Alabama · NCT06962488

• Lipoprotein(a) levels in adults with atherosclerotic cardiovascular disease in Russia

  We will measure Lipoprotein(a) levels in adults with atherosclerotic cardiovascular disease in Russia and their relatives to see how common high levels are and whether they link to higher heart and stroke risk.

  Recruiting at 20 sites Novartis · Chelyabinsk and 19 other locations · NCT06858332

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.